To establish a reliable relationship with shareholders, employees, and other stakeholders, a robust corporate governance structure is key. In addition, it is also crucial to ensure Moberg Pharma is managed responsibly, and in compliance with applicable laws, regulations, and best practices governing the company's operations.
In a constantly changing world, with a focus both internally and externally on good corporate governance, Moberg Pharma is working to continuously improve its corporate governance model. Good corporate governance leads to better quality in the decisions made by those who manage the business.
Moberg Pharma’s focus on product quality, the environment and sustainability, responsible leadership and ethical decision-making also contributes to a sustainable business and long-term value creation.
Following market approval in 13 EU countries and the launch that started 2024 in Sweden, Moberg Pharma is now in a transformation phase from a late-stage pharmaceutical development company to launching the competencies needed to be a company with pharmaceuticals on the market.
One focus area in 2024 was to work with continuity risks in the company’s operations, including securing a long-term supply of terbinafine. During the year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP), which is now available for MOB-015. Three product batches have been manufactured with terbinafine from the new supplier, where available stability data confirm MOB-015’s sustainability profile. All in all, the year produced further improvements in terms of corporate governance that even better prepare Moberg Pharma for the future. Corporate Governance Report 2024